These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 28483121)

  • 1. Effect of Weight on Parenteral Prostacyclin Analogues Dosing in Pulmonary Hypertension.
    Raeisi-Giglou P; Wang XF; Dakkak W; Bair N; Dweik RA; Tonelli AR
    Chest; 2017 May; 151(5):1189-1192. PubMed ID: 28483121
    [No Abstract]   [Full Text] [Related]  

  • 2. Transitioning from parenteral to inhaled prostacyclin therapy in pulmonary arterial hypertension.
    Ataya A; Somoracki A; Cope J; Alnuaimat H
    Pulm Pharmacol Ther; 2016 Oct; 40():39-43. PubMed ID: 27470680
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Transition from IV to subcutaneous prostacyclin: premature withdrawal?
    Shapiro S; Hill NS
    Chest; 2007 Sep; 132(3):741-3. PubMed ID: 17873184
    [No Abstract]   [Full Text] [Related]  

  • 4. Prostacyclin withdrawal in pulmonary hypertension #264.
    Bartlett C; Landzaat L;
    J Palliat Med; 2013 Feb; 16(2):204-5. PubMed ID: 23336356
    [No Abstract]   [Full Text] [Related]  

  • 5. Oral prostacyclin therapy for pulmonary arterial hypertension: another step forward.
    Waxman AB
    Circulation; 2013 Feb; 127(5):563-5. PubMed ID: 23307828
    [No Abstract]   [Full Text] [Related]  

  • 6. Safety and Tolerability of High-dose Inhaled Treprostinil in Pulmonary Hypertension.
    Parikh KS; Rajagopal S; Fortin T; Tapson VF; Poms AD
    J Cardiovasc Pharmacol; 2016 Apr; 67(4):322-5. PubMed ID: 26828324
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Role of prostacyclin and its derivatives in the treatment of pulmonary arterial hypertension].
    Osvaldo Cáneva J; Ossés JM
    Medicina (B Aires); 2003; 63(3):233-6. PubMed ID: 12876911
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Transition from intravenous or subcutaneous prostacyclin therapy to inhaled treprostinil in patients with pulmonary arterial hypertension: a retrospective case series.
    Enderby CY; Soukup M; Al Omari M; Zeiger T; Burger C
    J Clin Pharm Ther; 2014 Oct; 39(5):496-500. PubMed ID: 24806480
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Transition From Subcutaneous or Inhaled Treprostinil to Oral Treprostinil at Home in Patients With Pulmonary Arterial Hypertension: A Retrospective Case Series.
    Ackerbauer KA; Tandon R
    J Pharm Pract; 2018 Apr; 31(2):163-166. PubMed ID: 28464760
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transition from epoprostenol and treprostinil to the oral endothelin receptor antagonist bosentan in patients with pulmonary hypertension.
    Suleman N; Frost AE
    Chest; 2004 Sep; 126(3):808-15. PubMed ID: 15364760
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parenteral and inhaled prostanoid therapy in the treatment of pulmonary arterial hypertension.
    McLaughlin VV; Palevsky HI
    Clin Chest Med; 2013 Dec; 34(4):825-40. PubMed ID: 24267307
    [TBL] [Abstract][Full Text] [Related]  

  • 12. One-year experience with intravenous treprostinil for pulmonary arterial hypertension.
    Benza RL; Tapson VF; Gomberg-Maitland M; Poms A; Barst RJ; McLaughlin VV
    J Heart Lung Transplant; 2013 Sep; 32(9):889-96. PubMed ID: 23953817
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral treprostinil for the treatment of pulmonary arterial hypertension.
    de Lartigue J
    Drugs Today (Barc); 2014 Aug; 50(8):557-65. PubMed ID: 25187906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Prostacyclin and iloprost in aerosol form in severe pulmonary hypertension].
    Olschewski H; Walmrath D; Schermuly R; Ghofrani HA; Grimminger F; Seeger W
    Pneumologie; 1998 Jan; 52(1):3-7. PubMed ID: 9540363
    [No Abstract]   [Full Text] [Related]  

  • 15. Inhaled treprostinil for the treatment of pulmonary arterial hypertension.
    LeVarge BL; Channick RN
    Expert Rev Respir Med; 2012 Jun; 6(3):255-65. PubMed ID: 22788940
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transition from IV epoprostenol to subcutaneous treprostinil in pulmonary arterial hypertension: a controlled trial.
    Rubenfire M; McLaughlin VV; Allen RP; Elliott G; Park MH; Wade M; Schilz R
    Chest; 2007 Sep; 132(3):757-63. PubMed ID: 17400684
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension.
    Lang I; Gomez-Sanchez M; Kneussl M; Naeije R; Escribano P; Skoro-Sajer N; Vachiery JL
    Chest; 2006 Jun; 129(6):1636-43. PubMed ID: 16778286
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Infections by gram-negative bacilli in patients with pulmonary arterial hypertension treated with intravenous prostacyclin.
    Gómez Sánchez MA
    Arch Bronconeumol; 2013 Mar; 49(3):128-9. PubMed ID: 23127721
    [No Abstract]   [Full Text] [Related]  

  • 19. Conversion to bosentan from prostacyclin infusion therapy in pulmonary arterial hypertension: a pilot study.
    Steiner MK; Preston IR; Klinger JR; Criner GJ; Waxman AB; Farber HW; Hill NS
    Chest; 2006 Nov; 130(5):1471-80. PubMed ID: 17099026
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combining treprostinil and sildenafil in the treatment of pulmonary hypertension.
    Chua R; Keogh A
    Intern Med J; 2005 Nov; 35(11):684-5. PubMed ID: 16248867
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.